How CVS Health Corp. Makes Money

CVS Health operates one of the most complex and multi-layered business models in American corporate history — a structure that interweaves retail pharmacy economics, insurance underwriting, pharmaceutical distribution intermediation, and primary care delivery into four distinct but increasingly interdependent segments. Understanding how CVS makes money requires understanding each of these segments individually and then grasping the strategic logic behind connecting them. The Health Care Benefits segment, anchored by the Aetna brand, is CVS Health's insurance operations. This segment provides medical, pharmacy, dental, and behavioral health benefits to approximately 26 million medical members through commercial employer plans, individual and family plans sold on the Affordable Care Act exchanges, Medicare Advantage plans, and Medicaid managed care contracts. Revenue in this segment flows primarily from insurance premiums — the monthly payments collected from employers, government programs, and individuals in exchange for coverage. In fiscal year 2024, Health Care Benefits generated approximately $120 billion in premium revenues. The economic engine of insurance is the medical loss ratio (MLR) — the share of premium revenue paid out in claims. When MLR is low, the segment generates meaningful underwriting profit. When it rises — as it did sharply in 2024, reaching levels above 90 percent in some quarters due to elevated utilization in Medicare Advantage — the segment produces underwriting losses that can rapidly erase the value of the premium base. This dynamic drove much of CVS Health's profitability crisis in 2024. The Pharmacy & Consumer Wellness segment is the company's retail and mail-order pharmacy operation, encompassing the branded CVS Pharmacy storefronts, the MinuteClinic walk-in clinic network inside CVS locations, and the growing HealthHUB store format. This segment generated approximately $95 billion in revenues in fiscal year 2024. Revenue here comes from two primary sources: pharmacy dispensing (filling prescriptions in exchange for reimbursement from insurance plans and government programs, plus patient copays) and front-end retail sales (over-the-counter medications, personal care products, seasonal merchandise, and convenience goods). Pharmacy dispensing accounts for roughly 80 percent of this segment's revenues. The economics are challenging: retail pharmacy reimbursement rates have been squeezed for years by PBMs — ironically including CVS's own Caremark — which negotiate reimbursement on behalf of payers. Front-end retail has faced structural pressure from mass retailers and e-commerce. The MinuteClinic network, with approximately 1,100 locations, provides primary care, urgent care, and chronic disease management services, primarily serving patients who use CVS pharmacies. These clinics are important strategically for deepening patient relationships but remain a relatively small financial contributor compared to dispensing revenues. The Health Services segment, primarily anchored by CVS Caremark, is the company's pharmacy benefit management (PBM) operation and one of the largest and most financially consequential PBM businesses in the world. Caremark manages pharmacy benefits for health plan sponsors — employers, unions, government entities, and health insurers — processing more than 2 billion prescription claims annually. The PBM business model is layered and opaque. Caremark earns revenue through administrative fees charged to plan sponsors, spread pricing (the difference between what it charges a plan sponsor for a drug and what it pays the dispensing pharmacy), and rebates negotiated with pharmaceutical manufacturers that may or may not be fully passed through to plan sponsors depending on contract terms. In fiscal year 2024, the Health Services segment generated approximately $170 billion in revenues, though much of this figure represents drug costs flowing through Caremark's books rather than pure economic value created. Adjusted operating income is a more meaningful measure of economic contribution from this segment. Caremark also operates specialty pharmacy services for high-cost complex medications, a segment of rapidly growing importance as biologic and gene therapy drugs become more prevalent. The fourth pillar is the company's expanding primary care footprint through Oak Street Health, acquired in May 2023 for approximately $10.6 billion. Oak Street operates a value-based primary care model specifically designed for Medicare-eligible patients, predominantly in urban markets and underserved communities. Under value-based care arrangements, Oak Street receives a fixed per-patient capitated payment from Medicare Advantage plans to provide comprehensive primary care services. Its economics depend on managing total cost of care below the capitated payment — essentially running the clinical operation efficiently enough to generate a margin on the capitation. Oak Street had approximately 188 centers at time of acquisition and has continued expanding under CVS ownership. Financially, the segment is early-stage relative to CVS's other businesses, still investing heavily in center openings, but strategically represents a crucial link in CVS's integrated care thesis: if CVS can manage a patient's insurance coverage through Aetna, fill their prescriptions through Caremark and CVS Pharmacy, and provide their primary care through Oak Street, the company captures healthcare dollar from multiple angles while theoretically improving care coordination and reducing total medical costs. Cross-segment economics represent the final layer of the CVS business model — and the most controversial. The company's integrated structure means that Aetna plans can direct members to CVS pharmacies, Caremark can serve as the preferred PBM for Aetna, and Oak Street patients can be seamlessly referred into the broader CVS network. Critics, including regulators and competing health systems, argue that these vertical relationships create conflicts of interest, particularly in the PBM context, where Caremark's decisions about which drugs to cover and reimburse at what rates affect both payer clients and CVS's own retail pharmacy. Defenders argue that integration genuinely reduces friction, lowers costs, and improves health outcomes for patients who engage with the full CVS ecosystem. The empirical truth lies somewhere between these poles and is difficult to disentangle from the company's reported financial results. What is certain is that the model requires immense capital, operational complexity spanning multiple regulated industries, and a management team capable of simultaneously running a retail chain, an insurance company, a PBM, and a clinical care network — a challenge that has proved more demanding than investors initially anticipated when the Aetna deal closed in 2018.

CVS Health's growth strategy under CEO David Joyner centers on three interrelated priorities that represent a course correction from the acquisition-led expansion of the Lynch era toward more disciplined organic growth and operational integration. The first priority is deepening the integration of existing assets. For years, CVS assembled pieces — Caremark, Aetna, MinuteClinic, Oak Street — but cross-segment coordination remained incomplete. Joyner has emphasized building care management programs that connect Aetna members with Oak Street primary care, CVS pharmacists, and Caremark specialty pharmacy in coordinated pathways. The goal is to demonstrate, with concrete clinical and financial outcomes data, that integrated care actually reduces total medical costs — the foundational premise that justified the Aetna acquisition price in 2018. The second priority is accelerating Oak Street Health's expansion in a capital-efficient manner. Rather than opening new centers at maximum speed regardless of per-center economics, CVS is targeting markets where Medicare Advantage penetration is high, where Oak Street's value-based care model can capture the greatest risk adjustment upside, and where real estate and clinical staffing costs support attractive unit economics. Management has guided toward continued center openings while improving new center maturation timelines. The third priority is expanding digital health and pharmacy capabilities to compete with Amazon and other digital-first entrants. This includes investment in CVS's mobile app and digital prescription management, expansion of same-day and next-day delivery options, and development of digital chronic disease management programs that extend the clinical relationship beyond the physical store visit. These investments are growth-oriented but also defensive, aimed at retaining customers who might otherwise migrate to pure-play digital pharmacy alternatives.